End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
- 20 June 2009
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (18), 2905-2908
- https://doi.org/10.1200/jco.2009.22.4998
Abstract
Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.Keywords
This publication has 38 references indexed in Scilit:
- Response criteria for gliomaNature Clinical Practice Oncology, 2008
- Immediate post-radiotherapy changes in malignant glioma can mimic tumor progressionNeurology, 2004
- CT and MR Imaging after Placement of the GliaSite Radiation Therapy System to Treat Brain Tumor: Initial Experience2004
- Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p DeletionsJournal of Clinical Oncology, 2004
- Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomasAnnals of Oncology, 2003
- Continuous growth of mean tumor diameter in a subset of grade II gliomasAnnals of Neurology, 2003
- MR Imaging and Single-Photon Emission CT Findings after Gene Therapy for Human Glioblastoma2001
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999
- Steroid‐induced CT changes in patients with recurrent malignant gliomaNeurology, 1988
- Postoperative contrast enhancement in patients with brain tumorAnnals of Neurology, 1985